Astrocyte reactivity is disease-and stimulus-dependent, adopting either a proinflammatory A1 phenotype or a protective, anti-inflammatory A2 phenotype. Recently, we demonstrated, using cell culture, animal models and human brain samples, that dopaminergic neurons produce and secrete higher levels of the chemokine-like signaling protein Prokineticin-2 (PK2) as a compensatory protective response against neurotoxic stress. As astrocytes express a high level of PK2 receptors, herein, we systematically characterize the role of PK2 in astrocyte structural and functional properties. PK2 treatment greatly induced astrocyte migration, which was accompanied by a shift in mitochondrial energy metabolism, a reduction in proinflammatory factors, and an increase in the antioxidant genes Arginase-1 and Nrf2. Overexpression of PK2 in primary astrocytes or in the in vivo mouse brain induced the A2 astrocytic phenotype with upregulation of key protective genes and A2 reactivity markers including Arginase-1 and Nrf2, PTX3, SPHK1, and TM4SF1. A small-molecule PK2 agonist, IS20, not only mimicked the protective effect of PK2 in primary cultures, but also increased glutamate uptake by upregulating GLAST. Notably, IS20 blocked not only MPTP-induced reductions in the A2 phenotypic markers SPHK1 and SCL10a6 but also elevation of the of A1 marker GBP2. Collectively, our results reveal that PK2 regulates a novel neuron-astrocyte signaling mechanism by promoting an alternative A2 protective phenotype in astrocytes, which could be exploited for development of novel therapeutic strategies for PD and other related chronic neurodegenerative diseases. PK2 signals through its receptors on astrocytes and promotes directed chemotaxis. PK2-induced astrocyte reactivity leads to an increase in antioxidant and anti-inflammatory proteins while increasing glutamate uptake, along with decreased inflammatory factors.
functions , both the stimulus and the underlying mechanisms leading to astrocyte reactivity and transformation remain elusive. Therefore, ligands that lead to either a classical, proinflammatory A1 reactive state or an alternative, protective A2 reactive state may serve as potential therapeutics for neurodegenerative diseases.
Prokineticin-2 (PK2) is a small chemokine-like signaling protein that was originally found to potently contract gastrointestinal muscles (Li et al., 2001) . It is a mammalian homologue of both MIT1, a nonvenomous protein in mamba snake venom, and the frog skin protein Bv8 (Ferrara, LeCouter, Lin, & Peale, 2004; Schweitz et al., 1999) . Subsequently, two G protein-coupled receptors were identified as the prokineticin receptors PKR1 and PKR2 (Lin et al., 2002) . Signaling through these receptors is implicated in various physiological functions throughout the body, including hematopoiesis, angiogenesis, reproductive functions, innate immunity, and cardiomyocyte protection (Urayama et al., 2007) . PK2 also plays a role in circadian rhythms, olfactory bulb biogenesis (Ng et al., 2005; , energy expenditure and homeostasis , and neuroprotection (Landucci et al., 2016; Melchiorri et al., 2001 ).
PK2 expression is generally induced in areas of increased inflammation in the brain and gut (Watson et al., 2012) . We recently reported that dopaminergic neurons produce PK2 during early stages of neurotoxic stress as a potential compensatory reaction (Gordon et al., 2016) . We demonstrated that soluble PK2 is secreted from dopaminergic neurons treated in vitro with TNFα, in multiple in vivo mouse models of PD and in human postmortem PD patients (Gordon et al., 2016) . We also reported increased levels of PKR2 in the substantia nigra, and importantly, that exogenous administration of PK2 protected against MPTP-induced motor-deficits, dopamine depletion, and dopaminergic degeneration in animal models of PD. Previous studies also found gene expression in neurons to be higher for PKR2 than for PKR1 (Lin et al., 2002) . This pattern contrasts with astrocytes and microglia in the brain where PKR1 gene expression levels exceed those of PKR2 (Zhou, 2006) . Additionally, PK2 treatment induces cell proliferation and intracellular calcium mobilization in cultured astrocytes. Based on observations of soluble PK2 secreted from damaged dopaminergic neurons, we investigated the role of PK2 signaling in astrocyte reactivity and its functional significance.
| MATERIALS AND METHODS

| Reagents
Dulbecco's modified Eagle's medium (DMEM), MEM media, fetal bovine serum (FBS), L-glutamine, IRDye-tagged secondary antibodies, Hoechst nuclear stain, penicillin, streptomycin, and other cell culture reagents were purchased from Invitrogen (Gaithersburg, MD). Recombinant PK2 was purchased from PeproTech (Rocky Hill, NJ). The primary antibodies for PKR1, PKR2, and Nrf2 were ordered from Santa Cruz Biotechnology (Santa Cruz, CA). GFAP antibody was obtained from Millipore (Billerica, MA). We purchased the phosphorylated STAT6 and native STAT6 antibodies from Cell Signaling (Danvers, MA). The Arginase-1 antibody was ordered from Thermo Fisher (Waltham, MA). The GLAST antibody was generously provided by Dr. Yongjie Yang, Tufts University. Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). Fluo-4 calcium assay and CyQUANT ® kits were ordered through Invitrogen.
| Animal studies
All animal procedures were approved by Iowa State University's Institutional Animal Care and Use Committee (IACUC). Eight-to 10-weekold male mice weighing 25−30 g were housed under standard conditions for constant temperature (22 ± 1 C), relative humidity (30%), and a 12-h light cycle with food and water available ad libitum. All mice were prescreened for normal baseline performance during behavioral assessments conducted before randomly assigning animals to experimental groups. Investigators involved with data collection and analysis were not blinded to group allocation.
Stereotaxic injection of rAAV PK2: Stereotaxic surgery was performed exactly as previously described (Gordon et al., 2016) . Briefly, C57BL/6NCrl mice (8-10 weeks old) were anesthetized using a ketamine/xylazine mixture. The Angle Two computer-assisted stereotaxic system was used to guide a 10-μL Hamilton syringe needle to the caudate-putamen region of the striatum at the following stereotaxic coordinates in relation to Bregma (mm): −2 ML, 0.5 AP, −4 DV. After advancing the needle through a burr hole drilled in the cranium, 3 μL rAAV-PK2 or rAAV-GFP viral particles (9 × 10 12 total viral particles)
were injected into the brain. Animals were allowed to recover for 4 weeks to maximize viral gene expression before euthanization.
Subacute MPTP treatment paradigm: Mice received IS20 (10 mg/ kg/day) in a 50% Miglyol 812N and 50% water mix by oral gavage beginning 1 day before the MPTP treatment, then 5 days of co-treatment with MPTP (20 mg/kg/day, intraperitoneal injection), followed by IS20 treatment daily for another 6 days. Mice were sacrificed 24 h after final treatment. In contrast, control mice received an IS20-free 50% Miglyol 812N and 50% water mix, but otherwise were subjected to the same treatment paradigm. Striatum tissues were dissected out and used for gene expression studies.
| Cell culture
Primary mouse astrocytes were obtained from the whole brain homogenate of 0-to 3-day-old mouse pups. Astrocytes were collected, isolated, and maintained according to a previous method (Gordon et al., 2011) using DMEM media (10% heat-inactive FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM glutamate)
to grow the cells. Normal human astrocytes (NHA) were obtained from Lonza (Allendale, NJ) and grown according to company instructions in astrocyte growth media (AGM, CC-3186) from Lonza. Human U373 astrocytoma cells (ATCC) were grown in MEM media supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL), according to ATCC instructions. The NHA and U373 cells were maintained in an incubator at 37 C with 5% CO 2 .
| CRISPR/Cas9-based knockdown of PKR1 in U373 cells
The lentivirus-based CRISPR/Cas9 knockdown (KD) plasmid, pLVU6gRNA-Ef1aPuroCas9GFP-PKR1 with the PKR1 gRNA targeting exon 2, was purchased from Sigma-Aldrich (St. Louis, MO). To generate the PKR1 CRISPR lentivirus, the lenti-CRISPR/Cas9 PKR1 KD plasmid and control plasmid were transfected into 293FT cells using the Mission Lentiviral Packaging Mix from Sigma-Aldrich according to the manufacturer's instructions. The lentivirus was harvested 48 h post transfection and titers were measured using the Lenti-X p24
Rapid Titer Kit (Clontech, Mountain View, CA). For stable knockdown of PKR1 in U373 cells, cells were grown in six-well plates with a seeding density of 0.1 × 10 6 cells per well in growth media, and lentivirus was added to the media at an MOI of 100 and incubated for 24 h.
After 24 h, fresh media supplemented with puromycin (50 μg/mL) was added to the cells for stable cell selection.
| Quantitative RT-PCR
Primary mouse astrocytes or human U373 cells were seeded in 75-mm 3 flasks at 2.5 × 10 6 cells per flask. Treatments were performed in either MEM or DMEM media supplemented with 2% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), and 2 mM L-glutamine. Cells were treated for 8 h with recombinant PK2 (rPK2, 25 nM) alone or rPK2 cotreated with PC-7 (1 μM). After treatment, cells were collected, pelleted, and resuspended in lysis buffer with β-mercaptoethanol. RNA was isolated using the Absolutely RNA Miniprep kit (Stratagene, San Diego, CA). Reverse transcription was performed using a cDNA synthesis system (Applied Biosystems, Foster City, CA)
to convert the RNA into cDNA. Expression levels were determined using real-time PCR with Qiagen RT 2 SYBR Green master mix and validated qPCR mouse primers from Qiagen (Frederick, MD). For normalization of each sample, the mouse gene 18S rRNA (Qiagen Cat.
No. PPM57735E) was used as the housekeeping gene. The amount of each template was optimized empirically to maximize efficiency without inhibiting the PCR reaction. According to manufacturer's guidelines, dissociation curves and melting curves were run to ensure that single amplicon peaks were obtained without any nonspecific amplicons. The results are reported as fold change in gene expression, which was determined via the ΔΔC t method using the threshold cycle (C t ) value for the housekeeping gene and for the respective gene of interest in each sample (Livak & Schmittgen, 2001 ).
| Western blotting
Astrocytes were collected after treatment, lysed using modified RIPA buffer, homogenized, sonicated, and centrifuged as previously described (Kaul, Anantharam, Kanthasamy, & Kanthasamy, 2005; Kaul et al., 2003) . Supernatants were collected, protein concentrations determined and normalized between samples, then stored with loading buffer and DTT. Samples were run on a sodium dodecyl sulfate (SDS) gel electrophoresis. Normalized protein samples were loaded into each well and first separated in a 4% stacking gel and then through a 12%-18% resolution gel. Proteins were then transferred to a nitrocellulose membrane. After transfer, the membranes were blocked using Western blocking buffer (Rockland Immunochemicals, Pottstown, PA). Primary antibodies in blocking buffer were then added to the membranes and stored overnight at 4 C. A secondary antibody specific to the primary antibody was added (in either blocking buffer or in 5% low-fat dry milk solution) to the membrane for 1 h. Either β-actin or α-tubulin was used to confirm equal loading into each well of the gels. Densitometric determinations were made using the Odyssey infra-red imaging system (LI-COR, Lincoln, NE).
| Immunocytochemistry
For immunocytochemistry (ICC), cells were plated onto coverslips in 24-well plates coated with 0.1% poly-D-Lysine. After cells were treated, 4% paraformaldehyde (PFA) was used to fix the cells for 30 min. The cells were washed with PBS wash buffer. Then blocking buffer containing 2% BSA, 0.2% Triton X-100, and Tween was added to the wells for 1 h. The cells were incubated overnight with primary antibodies in 2%
BSA at 4 C. Next, an Alexa Fluor dye-conjugated secondary antibody in 2% BSA was added and incubated at RT on a shaker for 1 h. After washing, Hoechst counterstain was added to the cells for 5-6 min to label nuclei. Coverslips were washed several times then mounted onto slides with Fluoromount mounting media (Molecular probes, Eugene, OR).
Cells were imaged under an Eclipse TE2000-U inverted microscope (Nikon, Tokyo, Japan) with an SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI), and all images were processed in MetaMorph 5.7 (Universal Imaging, Downingtown, PA).
For histology, mice were anesthetized using ketamine-xylazine and then perfused with 4% PFA to fix the brain before being extracted and stored in 4% PFA at 4 C. After 48 h, brains were washed with PBS and placed in 30% sucrose for at least 24 h. The brains were then embedded in Optimal Cutting Temperature (OCT, Sakura Finetek USA, Torrance, CA) compound and frozen into blocks for sectioning.
Brains were sectioned on a cryostat (CryoStar NX70, Thermo Scientific) at −20 C and placed into cryosolution (30% sucrose, 30% ethylene glycol, and 1 × PBS). Sections were then washed with PBS and permeabilized with blocking buffer (2% BSA, 0.1% Triton X-100, and Tween) for 1 h at RT. Antibodies directed to the protein of interest were then incubated with the sections overnight at 4 C. After washing with PBS, sections were incubated with Alexa Fluor dyeconjugated secondary antibodies for 1 h at RT. After a final washing with PBS, Hoechst dye (1:5,000) was added to the sections for 5 min at RT to stain nuclei. Sections were then mounted on slides using Fluoromount according to the manufacturer's instructions before being visualized and imaged as described above.
2.8 | GFAP + cell count and morphological assessment GFAP diaminobenzedine (DAB) immunostaining was performed as previously described (Ghosh et al., 2012) . Briefly, endogenous peroxidases were inhibited, and the sections were blocked with normal goat serum and then incubated overnight with the primary GFAP antibody.
Secondary antibody was added for 1 h followed by incubation with ABC solution and finally 2 min in DAB substrate. Sections were mounted, air dried, dehydrated before incubation in xylene, and 
| Scratch-wound migration assay
The scratch-wound assay was performed according to Liang, Park, and Guan (2007) . Briefly, astrocytes were grown to a confluent monolayer in 6-well plates. Once the cells were fully confluent, a 1,000-μL pipette tip was used to scratch through the cells from top to bottom and from left to right, thereby forming a plus sign to identify similar imaging areas. Cells were triple-washed with serum-free media, treatments were added and wells were imaged for the 0-h timepoint. 10%
FBS serum containing media was used as positive control. Endpoint images were taken 24 h after treatment using an inverted fluorescence microscope (Nikon TE-2000U) . Measurement of the scratch width was randomly assessed in each group and expressed in microns.
This experiment was repeated 3 times using three wells per treatment.
| 2D chemotaxis assay
The chemotaxis assay was performed using Ibidi (Planegg, Germany)
2D chemotaxis chambers according to the manufacturer's guidelines.
The U373 astrocytoma cell line was seeded into the middle line of each chamber and allowed to adhere to the plate overnight. The 10% serum-containing DMEM growth media was washed twice with serum-free DMEM media, and then either serum-free media or rPK2 was introduced through one of the experimental reservoirs. The cells were imaged at 0 h to ensure that the cells were still attached and then reimaged hourly for 18 h at 10 × magnification. Images were taken using an inverted fluorescence microscope (Nikon TE-2000U) and collated using ImageJ software. Cells were tracked to measure migration parameters with the Ibidi Manual Tracking software. A minimum of 50 cells were followed for each treatment to determine overall migration parameters.
| Mitochondrial dynamics
To analyze mitochondrial energy dynamics in both primary mouse astrocytes and the U373 human astrocyte cell line, the XFe24 Seahorse analyzer (Agilent, Santa Clara, CA) was used to measure OCR and ECAR levels. Astrocytes were plated on Seahorse plates at 80,000 cells/well and allowed to attach overnight in growth media.
Cells were then triple-washed with serum-free DMEM media and 500 μL of treatment was added to the wells in serum-free DMEM. 
| Glutamate uptake assay
Primary mouse astrocytes were plated into a 24-well plate with 120,000 cells/well in serum-free DMEM media. The media was either untreated (controls) or treated with rPK2 or IS20. After 8 h, the treatment media was washed away with three washes of Krebs-Ringer's buffer. The cells were then incubated with 2 μCi radioactive glutamate for 15 min along with 100 μM L-glutamine in warm KrebsRinger's buffer. Media was removed and cells were triple-washed with ice cold Krebs-Ringer's buffer to stop uptake. Next, cells were lysed in 1N NaOH. Radioactivity was measured with a liquid scintillation counter (Tri-Crab 4000, Packard Instrument Co., Fallbrook, CA) after the addition of a 5-mL scintillation mixture to each vial. Specific glutamate uptake was expressed as mean counts.
| Data analysis
Data analysis was performed using Prism 4.0 (GraphPad Software, San Diego, CA). The data were first analyzed using one-way ANOVA and then Tukey's post-test was performed to compare all treatment groups. Differences of p ≤ 0.05 were considered statistically significant. Student's t-test was used when comparing two groups.
3 | RESULTS
| Receptors for secreted PK2 are expressed on primary mouse and human astrocytes
We recently demonstrated that the chemokine-like protein PK2 is upregulated in cultured dopaminergic neurons and in the substantia nigra of MPTP-treated mice (Gordon et al., 2016) . Here, we determined the role of PK2 in astrocytes. First, we examined whether PK2 receptors are present in primary mouse astrocytes. Using qRT-PCR, we found that the PKR1 and PKR2 genes are expressed in both mouse and human primary astrocytes, shown as ΔCt ( Figure 1a ).
However, PKR1 expression levels were 12-fold higher than PKR2 levels in both mouse and human astrocytes when calculated via ΔΔCt.
Additionally, we determined PK2 receptor protein levels in ICC shows PKR1 protein levels to be higher than PKR2 protein levels measured from the same samples on the same blot, which agrees with our qRT-PCR results ( Figure 1a ). The fluorescence microscopy images clearly show that PKR1 localizes to the outer cell membrane, whereas PKR2 is localized more toward the cell nucleus. These results are consistent with previously observed results in mouse astrocytes (Koyama et al., 2006) .
As Prokineticin receptors are G protein-coupled receptors, they can be linked to either Gi, Gq or Gs (Zhou, 2006) . Signaling through Gq induces intracellular calcium mobilization, which could lead to proliferation. Gs increases levels of cAMP, whereas signaling through Gi inhibits the production of cAMP. Therefore, we examined whether recombinant human PK2 (rPK2) could induce functional changes in isolated primary mouse astrocytes, such as increased intracellular calcium and cell proliferation. Astrocyte calcium signaling also has an important function in regulating synaptic strength and could be used as a measure of CNS dysfunction ( Alvarez-Ferradas et al., 2015) . Using the Fluo4-NW intracellular calcium dye, we demonstrate that rPK2 treatment induced a dose-dependent increase in intracellular calcium in primary mouse astrocytes ( Figure 1d ). These results demonstrate that rPK2 can elicit a signaling response in these astrocytes through prokineticin receptors. To test whether rPK2 treatment induces cell proliferation, we used CyQUANT dye to measure astrocyte numbers with or without rPK2 treatment. Mouse astrocytes were incubated with 25 nM rPK2 for 48 h. Recombinant PK2 treatment significantly increased cell proliferation when compared to untreated mouse astrocytes ( Figure 1e ). Taken together, these results suggest that PK2 functions to not only induce intracellular calcium levels by binding to prokineticin receptors but also to increase cell proliferation in primary astrocytes.
| Recombinant soluble PK2 induces wound healing in U373 and normal human astrocytes
As mobilization and induction of intracellular calcium levels are accompanied by astrocyte migration, we utilized a scratch-wound technique to determine if rPK2 induces astrocyte migration. After using a pipette tip to create a "scratch-wound" on a confluent layer of human U373 and normal human astrocytes, we calculated the difference in wound length at 0 h and 24 h after rPK2 treatment to indicate the distance that the cells migrated ( Figure 2a ). Recombinant PK2 treatment induced a significant increase in wound closure of both the U373 and normal human astrocytes relative to controls (Figure 2b ,c).
As expected, a dramatic increase in wound closure was observed in astrocytes grown in 10% FBS containing media, which was used as a positive control. These results demonstrate that rPK2 treatment induces wound healing in an injured human astrocyte cell line and in normal human astrocytes by promoting migration.
| Recombinant human PK2 induces chemotaxis in the U373 human astrocytoma cell line
In the injured or diseased CNS, astrocytes become activated and migrate to the site of injury. Several factors, including TGFβ and bFGF, have demonstrated the ability to cause astrocyte migration (Holland & Varmus, 1998; Huang, Wu, Liao, & Zhang, 2012) . As a chemokine-like protein, PK2 is known to be involved in the activation and migration of several systemic cell types, such as macrophages and monocytes (Ferrara et al., 2004; Martucci et al., 2006) .
Interestingly, PK2 has demonstrated the ability to activate the ion channel TRPV1 (Vellani et al., 2006) , which can increase astrocyte migration (Ho, Lambert, & Calkins, 2014) . Given its role in the migration of other cell types, in addition to our discovery that PK2
increases astrocyte wound healing, we examined whether PK2 could be a chemotactic factor for astrocytes. We used the Ibidi 2D chemotaxis slide to test PK2's chemotactic ability in the U373 human astrocytoma cell line. Cells were seeded into a strip in between two media reservoirs on the chemotaxis slide (Figure 3a) . One reservoir holds only media, while the other holds the chemotactic factor (rPK2) in media. The slide is designed to allow the chemotactic factor to reach the cells at a concentration curve that is stable for 48 h. If the protein causes chemotaxis in astrocytes, the cells in the middle strip will migrate more toward the chemotactic factorcontaining reservoir compared to the media-only reservoir.
The U373 cells were seeded on the slide 10 h before initiating treatment. Images were taken of the seeded cells before and after adding the treatment media to ensure cells were present and appeared healthy. Two experimental migration platforms were used, one with rPK2 in one media reservoir and control in the other. The second platform served as a negative control comparing control media in both reservoirs. Images were taken hourly at 10 × magnification for 18 h after the treatment was added to the reservoirs. The images were compiled and stitched together for manual tracking of cells.
Images at Hour 0 and 18 for the rPK2 migration platform reveal migration (Figure 3b ), which was quantified using the Ibidi manual cell tracking plugin for ImageJ. Beginning at Hour 0, one individual cell was manually selected and tracked at each subsequent timepoint to form a migration track for that cell. This process was repeated to compile migration metrics for over 50 cells for each experimental platform (Figure 3c ). Each cell's migration track was analyzed on both 2D axes, with movement toward or away from treatment reservoirs captured on the y-axis, which was oriented perpendicular to the middle line of The PK2 experimental platform resulted in a significant increase in the yFMI toward the reservoir containing rPK2, whereas the control platform showed no significant yFMI toward either reservoir, as expected ( Figure 3d) . The x-axis forward migration index (xFMI) showed that neither platform induced an increase in xFMI, or lateral movement in the cell reservoir. Therefore, rPK2 induced a directed migration toward one reservoir resulting from an increased yFMI and little to no change in the xFMI. PK2 also increased migration velocity, or distance travelled each hour (Figure 3e ), indicating that cell migration toward the PK2 reservoir was faster than the average control platform cell migration. Similarly, rPK2 treatment increased both the total accumulated distance of the astrocytes and the Euclidean, straight-line distance travelled from the origin (Figure 3f,g ). Directionality of cell Interestingly, rPK2 treatment induced increases in both OCR and ECAR levels compared to the control, producing a more energetic phenotype by increasing both energy production pathways in primary mouse astrocytes (Figure 4d ). When we conducted the same experiment in the U373 human astrocytoma cell line, we found similar results. Basal OCR (Figure 4f ) and ATP production ( Figure 4g ) were significantly increased with rPK2 treatment compared to the control.
The rPK2 treatment also increased ECAR levels in the U373 cell line, which along with the increased OCR, shifted cells toward a more energetic phenotype (Figure 4h ). Taken together, these data demonstrate that rPK2, by altering mitochondrial dynamics, can induce an energetic cell phenotype indicative of astrocyte reactivity. 3.6 | Lenti-PK2 overexpression induces the antioxidant response proteins arginase-1 and Nrf2
Next, we used a lentiviral delivery system to overexpress GFP-tagged PK2 or GFP-alone in primary mouse astrocytes (Figure 6a ). Gene expression analysis revealed that PK2 overexpression increased both arginase-1 and Nrf2, while iNOS gene expression was not altered (Figure 6b ). Examining the conditioned media of primary mouse astrocytes overexpressing PK2 revealed no change in the basal secretion of the proinflammatory cytokines IL-1β, IL-6, TNFα when compared to GFP controls (Figure 6c ). However, densitometric analyses of the Western blot revealed that Nrf2 protein level was significantly FIGURE 4 PK2 induces shift in mitochondrial dynamics and energy production. XFe24 Seahorse mitochondrial stress test on primary mouse astrocytes (a-d) and the U373 human astrocyte cell line (e-h). Analysis of mitochondrial respiration rate with the respiration plot (a and e), basal respiration (b and f ), and ATP production (c and g) showing that PK2 treatment significantly induced oxidative respiration in astrocytes. Cellular phenotype plot comparing OCR on the y-axis and ECAR on the x-axis (d and h) shows that PK2 treatment increased overall energy production in primary mouse astrocytes and the U373 human astrocyte cell line. At least four biological replicates per treatment and experiments were repeated at least two times. Asterisks denote statistically significant differences between PK2 and control treatments (*p < 0.05, and **p < 0.01) [Color figure can be viewed at wileyonlinelibrary.com] increased in PK2-GFP-overexpressing astrocytes but not in GFPoverexpressing astrocytes (Figure 6d ), similar to that observed with rPK2 treatment.
As STAT6 phosphorylation has been implicated in alternative activation of microglia and macrophages (Hu et al., 2015) , we measured STAT6 phosphorylation in PK2-induced astrocyte reactivity. PK2 
| PK2 overexpression induces GFAP upregulation and increases astrocyte numbers and soma size
Astrocyte morphology is a dynamic phenomenon that can have significant impact on neuronal synapses, and therefore represents an important measure of astrocyte reactivity (Heller & Rusakov, 2015) . Under basal conditions, astrocytes are characterized by thin cell bodies, elongated processes, and they express low levels of glial fibrillary acidic protein (GFAP). Upon reactivity, the cell soma and primary processes undergo hypertrophy, and astrocytes express higher levels of GFAP (Pekny & Pekna, 2014) . Previously, PK2 was found to activate immune cells and modulate systemic inflammation (Monnier & Samson, 2008) . 
| PK2 overexpression reduces total number of astrocyte processes and endpoints and promotes alternative reactivity in vivo
Another indication of astrocyte reactivity is the retraction of cytoplasmic processes (Kang et al., 2014) . As rPK2 could induce astrocyte migration in culture, retraction of processes and endpoints in astrocytes in vivo could be because those cells are currently migrating or preparing for migration. Using an ImageJ plugin developed to measure branching (Morrison et al., 2013) , we analyzed astrocyte processes following overexpression of PK2. GFAP DAB immunostaining images were uploaded into ImageJ (Figure 8a ), converted into binary images, and finally reduced to a skeleton image (Figure 8b ) that was then analyzed to show every branch (orange), junction (purple), and endpoint (blue) (Figure 8c ). This analysis allowed us to determine the length of processes and the number of branches, junctions, and process endpoints. AAV-PK2-GFP significantly reduced the number of astrocyte processes when compared to PBS control injection, whereas AAV-GFP did not result in a significant reduction (Figure 8d) . Also, the num- phenotype and S100a10, PTX3, SPHK1, and TN4SF1 are upregulated in A2 phenotype. We did not observe any change in mRNA levels of Serping 1 in AAV-PK2-treated compared to AAV-GFP-treated astrocytes (Figure 8f ). On the other hand, we observed significantly increased mRNA levels of PTX3, SPHK1, and TM4SF1, but only modestly increased S100a10 mRNA levels (Figure 8f ), in AAV-PK2-treated compared to AAV-GFP-treated astrocytes. Taken together, these results quantitatively demonstrate that PK2 overexpression can increase astrocyte reactivity in vivo and induce expression of genes associated with an alternatively reactive A2 phenotype.
3.9 | PKR1 agonist promotes alternative astrocyte reactivity in cell culture and MPTP animal models of PD Recently, Gasser et al. (2015) screened a library of PKR1 non-peptide agonist compounds for protecting cardiomyocytes. One of their compounds, IS20, activated the downstream prokineticin receptor signaling pathways, such as Akt and ERK, and protected cardiomyocytes against myocardial infarction (Gasser et al., 2015) . Since astrocytes mainly express PKR1, we determined if IS20 was capable of activating astrocytes in a similar manner to rPK2 and PK2 overexpression. Treatment with IS20 (10 μM) significantly increased mitochondrial respiration and ATP production ( Figure 9a ) in primary mouse astrocytes, suggesting a shift in the cellular energy phenotype toward a more energetic role compared to control treatment. These results indicate that IS20 can activate astrocytes in a similar manner to rPK2 treatment. Next, we found that mRNA levels of antioxidant genes, such as arginase-1 and Nrf2, were also significantly increased, whereas iNOS gene expression was decreased compared to the control (Figure 9b ).
We validated the gene expression results by examining the protein level of these key reactivity proteins using Western blotting techniques. In concordance with our qPCR results, GFAP, arginase-1, and Nrf2 significantly increased compared to control (Figure 9c ). Similar to AAV-PK2 expression and rPK2 treatment, IS20 (10 μM) did not alter mRNA expression levels of Serping 1, whereas IS20 30 μM led to a significant decrease in gene expression of this gene associated with the A1 phenotype (Figure 9d ). However, 10 μM IS20 induced increases in PTX3 mRNA levels (Figure 9e were suppressed by the nonpeptide PKR1 agonist IS20. 3.10 | Recombinant PK2 and IS20 treatments increased glutamate uptake via GLAST upregulation
Astrocytes are known to help protect neurons through multiple mechanisms, with one of those being the uptake of glutamate to prevent excitotoxicity (Sattler & Rothstein, 2006) . Astrocyte uptake of glutamate not only reduces the extracellular levels but can also induce astrocyte reactivity and alter multiple astrocyte functions (Morales & Rodriguez, 2012) , so it is important to examine astrocyte-mediated glutamate uptake. Interestingly, proinflammatory cytokines, such as TNFα, decrease the expression of glutamate transporters, especially GLAST (Dumont, Goursaud, Desmet, & Hermans, 2014) . Therefore, we used radiolabeled glutamate to determine whether rPK2 treatment could increase glutamate uptake by primary mouse astrocytes. Treating primary mouse astrocytes with rPK2 or the PKR1 chemical agonist IS20
for 8 h, along with IL-4 as a positive control, led to increased glutamate uptake compared to control cells (Figure 10a ). Although astrocytes that are cultured without the presence of neurons express low levels of GLT-1, GLAST is expressed at normal levels (Swanson et al., 1997) . We first confirmed that the primary mouse astrocytes did not express GLT- 
| DISCUSSION
Astrocytes become reactive during the neurodegenerative process.
Although the mechanisms underlying reactive astrogliosis are unclear, until recently it was viewed as a defensive reaction counteracting acute stress, restoring CNS homeostasis and limiting tissue damage.
Considerable evidence now shows that reactive astrocytes can shift to either a predominantly harmful or protective reactive state. Since astrocytes respond to multiple stimuli, it is possible that the harmful or beneficial effects of reactive astrocytes will be stimulus-or diseasespecific (Jang et al., 2013; Liddelow et al., 2017) . Proinflammatory cytokines such as TNFα and IL-1β stimulate astrocytes toward a predominantly harmful reactive state, whereas stimulation with the anti-inflammatory cytokine IL-4 can lead to a more protective or restorative reactive state (Jang et al., 2013) . These different reactive states have been termed A1, for the classical, proinflammatory state, and A2, for the protective, restorative state (Liddelow et al., 2017) .
Activated microglia can lead to A1 reactive astrocytes, which become cytotoxic and induce neurodegeneration. The A1/A2 terminology was derived from the similar M1 and M2 activation states found in macrophages and microglia. A1 astrocyte reactivity is evident in a wide range of neurodegenerative diseases, including PD, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis. On the other hand, A2 astrocytes can resolve inflammation and protect neurons and have primarily been found in ischemic injury, potentially resolving the inflammatory response (Liddelow et al., 2017) . It is therefore important to examine these reactive states and understand the mechanisms behind both A1 and A2 reactivity. Zamanian et al. (2012) found that over 50% of altered astrocyte gene expression differed between an ischemic injury model and an LPS inflammatory response model. Therefore, it is important to understand neuron-astrocyte signaling in pathological conditions such as
PD. Recently, we demonstrated that dopaminergic neurons produce and secrete high levels of the chemokine-like signaling protein PK2, as evidenced in animal models of PD and in postmortem tissues from human PD patients (Gordon et al., 2016) . In this study, we demonstrate that both types of prokineticin receptors are expressed by primary mouse and human astrocytes. PKR1 is expressed over 12-fold higher than PKR2 and is mainly colocalized to the outer cell plasma membrane. Similar to Koyama et al. (2006) , our in vitro treatments with human rPK2 increased intracellular calcium and cell proliferation in a primary astrocyte culture (Figure 1 ).
For the first time, we demonstrate that treatment with rPK2 increased astrocyte wound healing, chemotaxis, and shifted mitochondrial metabolism to a more energetic phenotype in both primary mouse astrocytes as well as in a human astrocyte cell line (U373). Also for the first time, we show that rPK2 treatment or PK2 overexpression reduced the expression of the pro-inflammatory factors IL-1β, IL-6, TNFα, and iNOS, and increased the expression of the antioxidant genes arginase-1 and Nrf2. Together, these are the first results demonstrating that a protein produced by neurons can increase cultured human astrocyte migration and shift primary mouse astrocytes to an anti-inflammatory A2 reactive phenotype. Although astrocyte reactivity has been used routinely as a marker for neurodegeneration and neuroinflammation, the consequences of this reactivity remain including regulation of the astrocyte response to injury (Jackson & Robinson, 2017) . Microglia treated with the purified endotoxin lipopolysaccharide (LPS) exhibit reduced basal and peak oxidative respiration rates (Orihuela, McPherson, & Harry, 2016) . Under basal conditions, astrocytes rely on glycolysis for energy production, but they switch to a more aerobic oxidative respiration once activated by certain stimuli (Hertz et al., 2007) . Inflammation from an acute brain injury was found to increase mitochondrial fragmentation in astrocytes and impair mitochondrial bioenergetics, while increasing the production of ROS (Motori et al., 2013) . Recombinant PK2 treatment of cultured primary mouse astrocytes or the U373 human astrocyte cell line increased the basal levels of oxidative respiration along with glycolysis ( Figure 4) . The rPK2-induced increase in basal respiration of astrocytes is consistent with our previous findings where rPK2 increased mitochondrial biogenesis in neurons (Gordon et al., 2016) .
However, it is more likely that reactive astrocytes require more energy for proliferation and migration, similar to previous reports for mitochondrial dynamics in microglia (Jiang & Cadenas, 2014; Orihuela et al., 2016) . Collectively, rPK2 treatment increased overall ATP production and basal respiration of cultured astrocytes, which indicates a possible alternative A2 reactive state of these cells due to inflammatory stimuli inducing the opposite effect.
Oxidative stress and excitotoxicity have been implicated in the progression of PD, with increased extracellular glutamate and ROS inducing dopaminergic neurodegeneration (Ambrosi, Cerri, & Blandini, 2014; Hwang, 2013) . Although astrocytes were traditionally viewed as support cells for the neurons of the CNS, evidence indicates that astrocytes can contribute to inflammatory damage of the CNS (Colombo & Farina, 2016; Liddelow et al., 2017) . Others report that overexpression of Nrf2 in astrocytes can protect dopaminergic neurons from cell death (Gan et al., 2012) . Stimulating the increased production of such antioxidant proteins in astrocytes could be a promising therapeutic avenue. Although the mechanisms behind Nrf2 induction in astrocytes are still being elucidated, communication from activated microglia is clearly involved (Correa et al., 2011) . Importantly, PK2 signaling in astrocytes does not increase inflammatory factors such as proinflammatory cytokines or iNOS. On the other hand, PK2 can increase protective factors such as the antioxidant proteins arginase-1, Mrc1, Prdx2 and, most importantly, Nrf2 at both the genetic and protein levels associated with the astrocytic A2 reactive phenotype. AAV-PK2 also induced increases in S100a10, PTX3, SPHK1, and TM4SF1 gene expression associated with induction of the anti-inflammatory A2 reactive phenotype. Interestingly, the nonpeptide PKR1 agonist IS20 activated cultured astrocytes and increased both arginase-1 and Nrf2 protein levels. Since this response occurs without elevating pro-inflammatory cytokines, then PK2-induced reactive astrocytes could lead to a more neuroprotective phenotype. Utilizing a CRISPR/Cas9 lentiviral knockdown technique, we found that almost completely knocking down PKR1 completely abolished the IS20-mediated increase in the anti-inflammatory mediators arginase-1 and Nrf2, while not affecting iNOS gene expression (Figure 9f ) . Therefore, the PK2-mediated signaling in astrocytes is mainly mediated by signaling through the PKR1 receptor. When we administered MPTP in a classical animal model of PD, IS20 cotreatment restored mRNA levels of the A2-phenotype genes SPHK1
and SCL10a6, which were otherwise severely reduced in animals treated with MPTP alone. Similarly, IS20 blocked MPTP-induced increases of GBP2 mRNA levels associated with the proinflammatory A1-phenotype. Furthermore, prokineticin signaling increases glutamate uptake by increasing the gene expression and protein level of GLAST in cultured astrocytes and could offer neuroprotection from excitotoxicity. Scavenging of glutamate by astrocytes is a key mechanism of neuroprotection, and increasing their ability to remove glutamate has been demonstrated to protect dopaminergic neurons (Yao et al., 2005) . Interestingly, Voloboueva, Suh, Swanson, and Giffard (2007) reported that mitochondrial impairment of astrocytes reduces their ability to uptake glutamate, resulting in exaggerated neuronal cell death in a co-culture system. Similarly, Hu et al. (2000) had shown that inflammatory cytokine treatment decreased glutamate uptake in cultured human fetal astrocytes. Ours is the first report of the cytokine-like signaling protein PK2 inducing antioxidant factors along with increased glutamate uptake in cultured astrocytes.
Previously, we demonstrated that dopaminergic neurons produced and secreted PK2 (Gordon et al., 2016) , which directly protected dopaminergic neurons through activation of the ERK and AKT pathways. In this study, we report for the first time that PK2 signaling can induce alternative A2 reactivity of astrocytes, stimulate astrocyte migration, induce the production of neuroprotective factors such as Nrf2, and increase glutamate uptake. These effects are mainly mediated via PKR1 signaling, with a PKR1 chemical agonist increasing the A2 phenotype and CRISPR/Cas9 PKR1 knockdown abolishing this increase. This opens the opportunity for exploiting prokineticin signaling to protect dopaminergic neurons in PD through alternative A2 astrocyte reactivity and increased antioxidant support. Further exploration of PK2 signaling in neuron-glia cross-talk could be an important avenue for developing novel therapeutic approaches to treating neurodegenerative diseases.
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